Abstract Aim: To compare triage strategies using different human papillomavirus (HPV) consensus and genotyping tests and a p16
Introduction
At least one of 14 recognised high risk types of the human papillomavirus (HPV) is present in almost all cervical cancers and persistent HPV infection with such high risk types is a necessary cause of disease. 1, 2 Cervical cytology testing is used by many established screening programmes with wide variation across Europe in the proportion of women referred to repeat cytology and colposcopy. 3 Low-grade cytology is associated with low positive predictive value (PPV) and many unnecessary colposcopic referrals. It has been suggested that triage tests are needed to ensure that women with high-grade cervical disease are identified but, at the same time, avoiding unnecessary over-referral to colposcopy. [4] [5] [6] [7] Triage is now routine in the United States of America (USA) 4, 6 and many other countries. Within England and Wales HPV testing is being introduced into the NHS Cervical Screening Programme (NHSCSP) for women with a borderline or mildly dyskaryotic cervical cytology result. 8, 9 Women who test positive for HPV triage will be referred to colposcopy and treated where necessary. However, it is not clear which HPV tests are most suitable for triage of cytology. We present data from two studies for women who were referred with a low-grade cytology and have been tested by repeat cytology and a range of HPV tests. We aim to compare different triage strategies among these women using potential triage tests including HPV DNA, HPV RNA, HPV genotyping and p16
INK4a tests.
Materials and methods
This analysis was restricted to women referred with a borderline or single mildly dyskaryotic smear who were enrolled in one of two studies (Fig. 1 ). All women included were referred with one or more abnormal cervical smears and had not been previously treated for cervical intraepithelial neoplasia (CIN). No HPV testing had been performed as part of routine screening of these women:
Predictors phase 1: 953 women were included in the original study and 559 (59%) were referred with a borderline or single mildly dyskaryotic smear. The details of the cohort are described elsewhere. 10 Samples were collected at colposcopy using PreservCyt Ò for repeat cytology and HPV testing by Hybrid Capture 2, PreTect HPV-Proofer, APTIMA, Abbott RealTime and p16
INK4a (tests described in full below). Predictors phase 2: 1099 women were included in the original study and 669 (61%) were referred with a borderline or single mildly dyskaryotic smear. Two cervical samples were taken because the number of tests proposed required more aliquots than could be obtained from a single sample. As in Predictors 1, samples were collected for repeat cytology and HPV testing at colposcopy using PreservCyt Ò . Full details of the cohort are described elsewhere. 11 HPV testing was performed using Hybrid Capture 2, PreTect HPV-Proofer, APTIMA, Abbott RealTime, p16
INK4a , Cobas 4800 and BD HPV tests (tests described in full below).
Where appropriate, histology samples for both studies were obtained at colposcopy. In addition, results from all histology taken within 9 months of the initial colposcopy were collected from the hospital. If histology was not taken due to a normal colposcopy then the histology result was considered negative. All available histology was centrally reviewed, blinded to the original result, and where discrepant readings occurred, further review was undertaken. Results presented here are based on the worst reviewed histology within 9 months of the initial colposcopy. Unless otherwise specified, all assays were conducted within the Wolfson Institute under the direction of LH and GT.
HPV testing

DNA based detection assays:
Hybrid Capture 2 (Qiagen) detecting 13 HR-HPV genotypes collectively. The assay is based on the hybridisation of HPV DNA to a 13 HR HPV RNA probe cocktail. Readings over 1 RLU are considered positive.
DNA based partial genotyping assays: INK4a testing was always performed after the other tests and therefore there was not always sufficient material.
Statistical analysis
We considered the worst histology finding within 9 months of the baseline visit. The main endpoint for Combined studies eligible women n=2052
824 not referred with borderline or single mildly dyskaryosis
Combined for analysis n=1228
Borderline dyskaryosis n=287
Single mild dyskaryosis n=941 sensitivity was taken as CIN3+ (CIN2+ was also considered). Specificity is only reported for <CIN2, as we do not consider the detection of CIN2 to be a 'false positive'. We considered pre-defined triage strategies which included single testing for each of the above tests; HPV testing in combination with p16
INK4a (i.e. positive for both HPV test and p16
INK4a
); testing for HPV type 16; testing for HPV types 16 and/or 18. Analyses were performed separately for women with (i) borderline dyskaryosis, (ii) a single mildly dyskaryotic cytology and (iii) all women combined. We calculated test positivity, PPV and sensitivity for CIN2+ and CIN3+ separately for each triage strategy and the specificity for women with <CIN2. Comparisons between tests were conducted by McNemar's test for matched pairs (Tables  S2 and S3 ).
All analyses were carried out using Stata 11.2 (StataCorp, USA).
Results
A total of 1228 women were included from the two Predictors studies. Of these, 941 (77%) were referred with a single mildly dyskaryotic cytology and the remaining 287 (23%) with borderline dyskaryosis (105/ 287 (37%) with a single borderline dyskaryosis and 182/287 (63%) with multiple borderlines). Full details are shown in Fig. 1 . The age range of the women included was from 18-67 years with a median age of 29 years (IQR 26-34 years).
The worst histology result within 9 months was CIN2 or worse for 203/1228 (17%) women with just under one half of these being CIN3 or worse (97/1228, 7.9%). There was a similar proportion of women with CIN3 or worse for those referred with a single mildly dyskaryotic smear and those with multiple borderlines (7.4% versus 6.6%, respectively, p = 0.69). However, a referral of single mild dyskaryosis was more associated with CIN2 than multiple borderlines (11% versus 4.7% p = 0.01). Full details of the worst histology result according to referral cytology are shown in Table 1 .
The proportion of women with an inadequate result varied by test. For Predictors phase I, p16
INK4a cytology was the last test to be performed on the sample and hence there was not always sufficient material to prepare a slide with adequate cellularity. Therefore, p16
INK4a had an adequate result for 73% of women, whereas all other tests had an adequate result for between 96% and 100%. Amongst those with an adequate result, positivity rates ranged from 73% to 80% for the DNA based tests. Of the RNA based tests, APTIMA had a positivity rate of 70% and PreTect HPV-Proofer was much lower at 34%. p16
INK4a was also less often positive than the DNA based tests and APTIMA at 54% ( Table 2 ). The proportion testing positive amongst those positive on other tests was lower for p16 INK4a and PreTect HPVProofer (range from 56-68% and 43-48%, respectively). All other tests had a positivity ranging from 87% to 99% amongst those positive for other tests.
Sensitivity, specificity and PPV of the different testing strategies are reported in Table 3 and summarised graphically in Fig. 2 . Five tests had a sensitivity of 99% or higher for CIN3+: Hybrid Capture 2, Abbott RealTime, BD HPV, Cobas 4800 and APTIMA. All these tests were significantly more sensitive than p16 INK4a or PreTect HPV-Proofer alone but had a lower specificity for <CIN2 (between 23.3% and 34.7%).
Requiring p16
INK4a to be positive in addition to the highly sensitive HPV tests increased specificity to between 58.1% and 63.2% although sensitivity for CIN3+ was reduced for each of the tests by around 15%. Furthermore, requiring either PreTect HPVProofer or p16
INK4a to be positive as well as the HPV test gave lower specificity (52.6% to 58.7%) but with sensitivities between 94.8% and 100%.
Type-specific genotyping reduced sensitivity for CIN3+ further still (69.1% to 79.6% for type 16/18; 68.8% to 75.5% for type 16 only). However, testing using 16 or 18 reduced the proportion of women without CIN2+ who tested positive to between 17.0% and 26.3%, while typing for 16 alone reduced the proportion of test positive women without CIN2+ to 12.4-18.7% with a higher PPV between 39.1% and 45.3%. By Table 1 Results of referral smear and worst reviewed consensus histology within 9 months of the baseline cytology.
Histology result
Referral cytology Table S1 shows performance of different strategies according to referral cytology result. The majority of women were referred with a single mildly dyskaryotic cytology, hence these results are similar to the overall results although with a slightly lower specificity for <CIN2. Approximately two-thirds of those referred with a borderline smear had previous cervical abnormalities.
There was a high concordance between the Abbott RealTime PCR, BD HPV and Cobas 4800 assays, with kappa values in excess of 0.85 for all pairwise comparisons (Table S2 ). There was also a good agreement comparing Hybrid Capture 2 and APTIMA with these other HPV-DNA tests (kappa values ranging from 0.63 to 0.77) but PreTect HPV Proofer and p16
INK4a were less often positive. Kappa values for all tests for type 16 were high, with kappa values above 0.8 (Table S3 ).
Discussion
This study compared several different tests in samples taken at the same time to evaluate different triage strategies. An ideal triage test should ensure that women with high-grade cervical disease are identified but avoid unnecessary over-referral to colposcopy.
Other studies have considered one or more HPV tests amongst women with low-grade cervical abnormalities but none have directly compared such a broad range of different tests. The ASCUS-LSIL Triage Study (ALTS) was a multi-centre clinical trial evaluating management strategies amongst 3488 women referred with ASCUS and 1572 with LSIL. Women were randomly assigned to immediate colposcopy, cytology or HPV testing using Hybrid Capture 2.
12 A high proportion (83%) of women referred with LSIL tested positive for HPV. 4 The women referred with ASCUS had a similar sensitivity to colposcopy but with approximately half the number of colposcopic referrals. 5 A study of 810 retrospectively collected samples of ASC-US and LSIL cases (roughly comparable to borderline and mild dsykaryosis) compared the performance of p16
INK4a with HPV testing (Hybrid Capture 2) on the same specimen. 13 For p16 INK4a cytology, the sensitivity for CIN2+ was 92.6% and 92.2%, respectively for ASC-US and LSIL and for HPV testing was 90.1% and 95.7%, respectively. The specificity for CIN2 was higher for p16
INK4a than HPV testing (63.2% versus 37.8% for ASC-US and 37.3% versus 18.5% for LSIL). Table 2 Overall positivity (Numbers are test 1 positive given that test 2 is positive). These results show a higher sensitivity but lower specificity for p16 INK4a testing than we have shown. However, within Predictors 1, as the p16
INK4a testing was the last to be evaluated, the high number of inadequate samples due to insufficient material should mean that these results are interpreted with caution. For Predictors 2 alone, p16
INK4a had a valid result for 589/669 (88%) of samples with 76.2% sensitivity for CIN2+ (83.7% for CIN3+) and 57.2% specificity.
The ATHENA study 6 compared Hybrid Capture 2 with Cobas 4800 in 1923 women with ASC-US cytology. The Cobas 4800 HPV test had a comparable performance for CIN2+ compared with the Hybrid Capture 2 test (sensitivity 90.0% vs. 87.2%; specificity 70.5% vs. 71.1%, respectively). Positivity for the two tests was considerably lower than seen in our study almost certainly due to the fact that this population included women with only a single ASC-US cytology (the majority of women in our study were referred with multiple borderline smears or a mildly dyskaryotic smear).
In this study, five HPV tests alone (Hybrid Capture 2, Abbott RealTime PCR, BD HPV test, Cobas 4800, APTIMA) had a very high sensitivity when considered in a triage setting ranging from 99% to 100% for CIN3+. These highly sensitive tests have a lower specificity but could reduce the number of referrals to colposcopy, in the population of women currently referred, by 20% to 30%. We also found that specificity improved by another 20-30% if only referring women testing positive for HPV type 16 or p16
INK4a . This strategy had little impact on sensitivity for CIN3+ although sensitivity for CIN2+ was slightly reduced. Other, less sensitive triage tests (p16 INK4a and PreTect HPV-Proofer) could reduce the number of unnecessary referrals by a further 15-25% but miss between 15% and 30% of CIN3+. It is known that many CIN2 and some CIN3 lesions will regress spontaneously and it cannot be excluded that tests with lower sensitivity still identify those lesions which are destined to progress to cancer. Nevertheless, these strategies would need to be combined with early recall when tests are negative. Since in the NHSCSP triage protocol women who have a negative HPV test will be returned to routine (three or five yearly screening), it is important that disease is not missed. If HPV was the primary screen then further testing amongst HPV positive women for HPV high-risk type 16 and p16
INK4a may be important strategies to determine which women to refer to colposcopy, especially amongst those with a negative cytology. This study included only women from Predictors 1 and Predictors 2 10,11 who had been referred to colposcopy with low-grade abnormalities and does not address women with low-grade abnormalities who were not referred (such as those with a single borderline dyskaryotic cytology). Triage of these women with the above tests is likely to increase referrals to colposcopy but this has not been addressed in this study. In the new proposals from the NHSCSP women with a single cytology showing borderline dyskaryosis would receive further HPV testing and are likely to have a lower rate of disease than women in this study. One further limitation of this study is that HPV testing did not affect future screening of the women and we have no subsequent test results. A recent study published by Rijkaart et al. and HPV testing strategies. Triage of HPV positive women with cytology, followed by repeat cytology yielded a high negative predictive value and modest colposcopy referral rate.
This study adds to further publications of these data and allows direct comparison of tests and combinations of tests in a triage setting. We have shown that five HPV tests had a very high sensitivity when considered in this setting and could still reduce the number of referrals to colposcopy by 20-30%. Other triage strategies could reduce the number of unnecessary referrals further but with a lower sensitivity for CIN3+ which would require combination with an earlier recall for screening.
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